| 000 | 01455 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513194734.0 | ||
| 264 | 0 | _c20000207 | |
| 008 | 200002s 0 0 eng d | ||
| 022 | _a0390-6078 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRandi, M L | |
| 245 | 0 | 0 |
_aLeukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents. _h[electronic resource] |
| 260 |
_bHaematologica _cNov 1999 |
||
| 300 |
_a1049-50 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxyurea _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xchemically induced |
| 650 | 0 | 4 |
_aLeukemia, Myelomonocytic, Chronic _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xchemically induced |
| 650 | 0 | 4 |
_aNeoplasms, Second Primary _xchemically induced |
| 650 | 0 | 4 |
_aPhosphorus Radioisotopes _xadministration & dosage |
| 650 | 0 | 4 |
_aPipobroman _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xcomplications |
| 700 | 1 | _aFabris, F | |
| 700 | 1 | _aGirolami, A | |
| 773 | 0 |
_tHaematologica _gvol. 84 _gno. 11 _gp. 1049-50 |
|
| 999 |
_c10509746 _d10509746 |
||